A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

Despite showing a great promise in the field of nanomedicine, nanoparticles have gained a
significant attention from regulatory agencies regarding their possible adverse health effects …

Background: Inflammation is a prominent feature of arrhythmogenic cardiomyopathy (ACM),
but whether it contributes to the disease phenotype is not known. Methods: To define the …

Cardiotoxicity is a severe side effect of drugs that induce structural or electrophysiological
changes in heart muscle cells. As a result, the heart undergoes failure and potentially lethal …

Modeling of human organs has long been a task for scientists in order to lower the costs of
therapeutic development and understand the pathological onset of human disease. For …

Cardiovascular diseases (CVDs) are a class of disorders affecting the heart or blood
vessels. Despite progress in clinical research and therapy, CVDs still represent the leading …

Ischemic heart disease, also known as coronary artery disease (CAD), poses a challenge for
regenerative medicine. iPSC technology might lead to a breakthrough due to the possibility …

One of the obstacles in studying the pathogenesis of hypertrophic cardiomyopathy (HCM) is
the poor availability of myocardial tissue samples at the early stages of disease …

Human pluripotent stem cell-derived cardiovascular progenitor cells (hCVPCs) and
cardiomyocytes (hCMs) possess therapeutic potential for infarcted hearts; however, their …

Relevant, predictive normal, or disease model systems are of vital importance for drug
development. The difference between nonhuman models and humans could contribute to …